Study Looks at Impact of Biosimilars on Cancer Treatment

Ipsos Healthcare has launched a multi-stakeholder impact study to illuminate the impact on cancer treatment of biosimilars.

Developed in response to the ongoing launch of oncology biosimilars in US and European markets, the syndicated study aims to combine robust patient-level data with perceptual research among doctors and payers and enable forecasting of the uptake of biosimilars in each country.

Mark Scazafave, Head of Ipsos's Americas & European Oncology Monitors, commented: “Payers will play an important role in the evolution of access to biosimilars. It is therefore essential to understand their perceptions as well as the potential leverage points that exist during the approval process, and how this differs by country.”